CERVOMED INC. - COMMON STOCK

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

10 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

27 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Key Senior Leadership Appointments

13 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

12 ноя 2024 07:00:01 Источник Nasdaq GlobeNewswire

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

08 ноя 2024 09:55:32 Источник Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

07 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

04 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

29 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

15 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

02 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

26 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

27 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

22 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

12 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

30 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

29 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference

17 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

11 июл 2024 08:51:12 Источник Nasdaq GlobeNewswire

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

24 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire